Sperm protein 17 targeting for epithelial ovarian cancer treatment in the era of modern immunoengineering

Enhanced Electrochemical Biosensing of the Sp17 Cancer Biomarker in Serum Samples via Engineered Two-Dimensional MoS2 Nanosheets on the Reduced Graphene Oxide Interface

“…Recent investigations have suggested that Sp17 was abnormally expressed in a variety of malignant tumors such as esthesioneuroblastomas, esophageal squamous cell carcinomas, ovarian cancers, multiple myelomas, and numerous histological variants associated with human nervous system (NS) malignancies, which include meningeal and neuroectodermal tumors. , In normal human beings, the serum Sp17 concentration has been recorded up to 64–2400 pg mL –1 , whereas in various types of cancer patients, the serum Sp17 concentration is found to be more than 6000 pg mL –1 . For the diagnosis, a cutoff value of 50–8000 pg mL –1 has been reported for various types of cancers such as ovarian, head, and neck cancers and endometrial and cervical cancers. ,, Thus, Sp17 acts as a cancer biomarker and can be found in the plasma or serum of patients with a wide range of pathological disorders when combined with its tumor-specific expression.…”

“…For the diagnosis, a cutoff value of 50−8000 pg mL −1 has been reported for various types of cancers such as ovarian, head, and neck cancers and endometrial and cervical cancers. 10,12,13 Thus, Sp17 acts as a cancer biomarker and can be found in the plasma or serum of patients with a wide range of pathological disorders when combined with its tumor-specific expression. Several detection techniques, including enzyme-linked immunosorbent assay (ELISA), 14 immunohistochemical analysis, 15 and flow cytometry, 16,17 have been employed to study thoroughly Sp17 as a biomarker.…”